Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig P Carden

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 5, 2007
Information about cancer clinical trials: an analysis of Internet resourcesCraig P Carden, Michael Jefford, Mark A Rosenthal
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
The Lancet. Oncology|December 17, 2008
Eligibility of patients with brain metastases for phase I trials: time for a rethink?Craig P Carden, Roshan Agarwal, Frank Saran, et al.
Current Opinion in Pharmacology|July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancerTimothy A Yap, Craig P Carden, Gerhardt Attard, et al.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|June 5, 2007
Information about cancer clinical trials: an analysis of Internet resourcesCraig P Carden, Michael Jefford, Mark A Rosenthal
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
The Lancet. Oncology|December 17, 2008
Eligibility of patients with brain metastases for phase I trials: time for a rethink?Craig P Carden, Roshan Agarwal, Frank Saran, et al.
Current Opinion in Pharmacology|July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancerTimothy A Yap, Craig P Carden, Gerhardt Attard, et al.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
Pageof 2